MedImpact Achieves Low Medicare & Medicaid Trend
MedImpact Achieves Low Medicare & Medicaid Trend in Spite of CMS Reports of Skyrocketing Drug Costs
The Centers for Medicare & Medicaid Services (CMS) released this week that the agency spent $174 billion on prescription medications — 23% of its budget — in 2016, up from $109 billion in 2012.
In conjunction with the expenditure news, CMS announced its newly redesigned Drug Spending Dashboard, which provides year-after-year information on Medicare and Medicaid drug usage and costs as part of a wide-reaching federal effort to lower the cost of prescription drugs in America.
The CMS announcement also highlighted that Medicare and Medicaid continue to face persistent double-digit increases on blockbuster insulin products.
MedImpact Industry Insights: Insulin & Diabetes Trends
MedImpact’s Annual Trend Report also revealed that insulins dominated top diabetes agents in Medicare in 2017 — accounting for nearly 10% of total spend. The diabetes therapeutic class accounted for 20% of total spend in Medicare
Likewise in Medicaid, diabetes — along with asthma/COPD agents — monopolized 9 out of the 10 top traditional Medicaid spend agents, with insulins accounting for nearly 9% of total Medicaid spend.
In fact, Januvia marked the only non-insulin diabetes agent to make the top 10 list for traditional drugs in both Medicare and Medicaid lines of business.
In spite of rising drug prices for established drugs and blockbuster innovator drugs, MedImpact achieved record-low drug trend across commercial, Medicare and Medicaid lines of business in 2017. Commercial plans saw the lowest trend increase – just 1.6% compared to 2.9% in 2016. Medicare plans saw only a 1.8% trend increase and Medicaid plans a 2.8% increase.
For in-depth insights on top therapeutic classes and to access the list of Top 10 traditional and specialty drugs across the Commercial, Medicare and Medicaid lines of business, down our 2017 Annual Trend Report.